About Co-High

Co-High Investment Management Limited ("Co-High"), incorporated in Cayman Islands with business office in Hong Kong, is an asset management company with a primary strategy focus on the Greater China region. Leveraging the new economy, industrial upgrading, One Belt One Road and the other China's frontier development, Co-High aims to discover new opportunities in the nation's emerging industries through active value-adding services, creating sustainable value to our portfolio companies, investors, partners and the society.

Recent News

  • CCEF Invested Company YIXIA Technology is on the List of QUESTMOBILE “2017 App Value Rank”

    YI live under YIXIA is solely awarded the “2017 Tier-2 Cities’ Most Favorite Top 10 App in China mobile Internet” and “2017 the Post-00s’ Most Favorite Top 10 App”.

    more


    CCEF Invested Company YIXIA Technology is on the List of QUESTMOBILE “2017 App Value Rank”

    2018-01-18

    In 17 January, the most authoritative third-party data organization - QuestMobile published “2017 China Mobile Internet Report”. In the report, YIXIA entered the top 10 of “2017 App Value Rank” by its outstanding performance. YIXIA has become the biggest winner in the mobile video realm. YI live under YIXIA is solely awarded the “2017 Tier-2 Cities’ Most Favorite Top 10 App in China mobile Internet” and “2017 the Post-00s’ Most Favorite Top 10 App”. At the same time Miaopai under YIXIA is awarded “2017 the Post-90s’ Most Favorite Top 10 App”. Moreover, Yi Live and Miaopai are both shortlisted for the “2017 Top Players of China Mobile Internet Flow”, indicating their leadership in innovation and ecology. YIXIA is the only company with two products on the list. The achievement is inseparable of YIXIA’s hard work and continuously building in new mobile video ecology.

    YIXIA Technology is the earliest enterprise exploring the short video business in China. They focus on users experience and are committed to building a new short video ecosystem. Now, YIXA has created a mobile video ecosystem by its products Miaopai, Yi Live and Xiaokaxiu. By cooperating with the biggest social media platform Weibo, Miaopai and Yi Live has achieved dominance in web traffic and become an innovative leader in short video sector.

    Co-High Investment Management Limited (“Co-High”) and China Cultural and Entertainment Fund L.P.(“CCEF”) are both the investors of YIXIA Technology.


    Co-High Investment Management Limited and CCEF are both the investor of YIXIA technology.

  • Co-High Invested Company Oxford Nanopore Technologies Receives Investment from Amgen

    On October 18, 2018, global biotech giant Amgen announced its equity investment of £50 million in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology.

    more


    Co-High Invested Company Oxford Nanopore Technologies Receives Investment from Amgen

    2018-10-18

    On October 18, 2018, global biotech giant Amgen announced its equity investment of £50 million in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology.

    Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores (nano-scale holes made by proteins contained within a synthetic membrane) in combination with electronics to perform direct, real-time sequencing of DNA and RNA. The technology ranges in scale from pocket-sized to very high throughput benchtop devices and can sequence very long fragments of DNA or RNA, which has a number of benefits in genomic analysis.

    The investment in Oxford Nanopore aligns with Amgen's strategic focus on using human genetics to deliver new medicines to patients. Amgen subsidiary deCODE Genetics, a world leader in human genetics, uses Oxford Nanopore's sequencing technologies to conduct genome research, including the identification and validation of new targets.

    "The study of human genetics continues to uncover insights into the diseases we face as a society," said Kári Stefánsson, founder of deCODE Genetics. " Oxford Nanopore's long-read sequencing capability creates a window into parts of the genome that have been out of reach, as well as giving us a much better handle on structural variants that confer risk of a wide variety of diseases. We have used Oxford Nanopore technology to sequence several hundred human genomes and continue to see the promise of this emerging technology."

    "As a biotechnology pioneer, Amgen has demonstrated what can be achieved for society through innovation and a deep understanding of genetics," said Gordon Sanghera, chief executive officer of Oxford Nanopore. "We are delighted to welcome them as a shareholder."

    Nanopore technology is uniquely scalable. MinIONTM, the only pocket-sized sequencer, can be used to sequence in any location. In addition, Oxford Nanopore has developed benchtop, on-demand, high-throughput devices such as PromethIONTM designed for very large projects or large numbers of samples.

    This investment will be effected through the purchase of £50 million ($66 million) of ordinary shares in Oxford Nanopore based on the same price per share as the primary fundraising announced in March 2018.

  • Co-High Invested Company Promethera Biosciences Completes Series D Financing

    Mont-Saint-Guibert, Belgium, and Tokyo, Japan, May 7, 2019 – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the closing of a €40 million (JPY4.94 billion) Series D financing.

    more


    Co-High Invested Company Promethera Biosciences Completes Series D Financing

    2019-05-07

    Mont-Saint-Guibert, Belgium, and Tokyo, Japan, May 7, 2019 – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the closing of a €40 million (JPY4.94 billion) Series D financing. The round was co-led by new Japanese investors ITOCHU Corporation and Shinsei Capital Partners. MEDIPAL HOLDINGS CORPORATION (Japan), Mirae Asset Capital (Korea), the family office Six Snow (Luxembourg), Korea Investment Partners (Korea), Ci:z Investment LLP (Japan) are joining the round as well as Belgian private investors. Promethera’s existing investor, Mitsui & Co. Global Investment, Inc. (MGI) also participated in the financing. Proceeds from the financing will accelerate the company’s ongoing HepaStem clinical program in ACLF and the launch of the company’s first clinical trial in NASH.

    “The financial support of our new and existing investors, with their expertise in cell therapies and wide Asian and global networks, will greatly help us as we efficiently advance the world’s first cell-based treatment for ACLF and NASH through clinical trials,” said John Tchelingerian, PhD, President and CEO of Promethera. “Our clinical trial in late stage NASH will soon be initiated first in Europe and is expected to expand to the US and Asia. We are excited to see how our HepaStem drug candidate can make a difference in the lives of patients with severe liver diseases. Overall, we are looking at a transformational period for our company and the financing puts us in a great position to execute our plans.”

    “Promethera has taken great steps to increase and bolster our relations and operations in Asia, and specifically in Japan and Korea, so we can benefit from the openness to stem-cell therapeutics in this area of the world,” said Mutsuki Takano, Group CFO and General Manager of Promethera’s Japan branch. “This territorial move has already started showing results, with our shareholder base growing significantly in Asia not least through this financing round.”

    HepaStem consists of liver stem cells that are obtained from ethically donated healthy human livers and expanded under cGMP conditions in production. The product candidate is currently being evaluated in a phase 2a clinical trial in the indication ACLF with first safety and efficacy results being presented recently at The International Liver Congress 2019 (EASL) as part of a late-breaking oral presentation. In addition to its cell-based approaches, HepaStem and H2Stem, Promethera is advancing a portfolio of complementary biologics approaches including the anti-TNF-R1 antibody Atrosimab.

    About Promethera Biosciences

    Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline (HepaStem and H2Stem), we develop antibody technologies such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland)

Investment Team

Top notch investment team with excellent vision and enriched experience in post-investment management and capital.

Contact Us

Room06, 35/F, The Centrium, 60 Wyndham Street, Central, Hong Kong
info@co-high.com
More Info